Table 5. Onset of IAT and ATWB events.
*Combination of any two or more CTLA-4 inhibitors, PD-1 inhibitors, and PD-L1 inhibitors; p value calculated by rank sum test; †Any other antineoplastic treatment not belonging to the class of ICIs specifically listed.
ATWB, elevated AT levels along with elevated bilirubin; CTLA-4, cytotoxic T-lymphocyte–associated protein 4; IAT, isolated elevation of AT levels; ICI, immune checkpoint inhibitor; ICI Comb, combinations of ICIs; PD-1, programmed cell death 1; PD-L1, programmed cell death ligand 1; SD, standard deviation.
| IAT (days) | ATWB (days) | |||
| Median (Min–Max) | Mean (SD) | Median (Min–Max) | Mean (SD) | |
| All treatment courses | 51 (1–1,256) | 87 (114.0) | 42 (1–1,256) | 77 (118.9) |
| CTLA-4 inhibitors | 63 (1–406) | 70 (62.9) | 48 (5–126) | 50 (34.8) |
| PD-1 inhibitors | 44 (1–1,256) | 90 (127.3) | 40 (1–1,256) | 79 (136.2) |
| PD-L1 inhibitors | 52 (1–518) | 78 (97.9) | 39 (1–122) | 45 (38.1) |
| ICI Comb* | 61 (1–759) | 78 (85.8) | 49 (1–302) | 62 (51.1) |
| ICI plus antineoplastic† | 56 (1–748) | 92 (107.5) | 59 (1–550) | 96 (117.2) |
| p value | 0.0986 | 0.5301 | ||